# Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

> **NCT05256797** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 353980 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT05256797
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-03
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 353980 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256797, "Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05256797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*